Zhuhai, China — September 7, 2026
Rezubio announced the successful first cohort dosing of RZ-520 in a Phase 1 clinical trial following investigational new drug (IND) clearances from both the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA). The clinical study is evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RZ-520 in healthy volunteers, marking an important transition of the company’s novel inhaled therapy from preclinical development into human clinical testing. RZ-520 is being developed as a potential treatment for chronic respiratory diseases, with Rezubio aiming to establish a differentiated therapeutic profile through localized delivery to the lungs and limited systemic exposure. The simultaneous regulatory clearances in the United States and China, together with first-patient dosing, represent a significant development milestone for Rezubio and its proprietary Membrane-Anchored Drug Design (MADD) platform.
Rezubio Advances Second MADD-Derived Clinical Asset
RZ-520 is the second clinical-stage asset developed through Rezubio’s proprietary MADD platform, further expanding the company’s pipeline of tissue-targeted therapeutic candidates. The platform is designed to engineer molecules capable of achieving prolonged local residence within targeted tissues while optimizing pharmacokinetic characteristics and minimizing unwanted systemic distribution. For RZ-520, the company is pursuing an inhaled approach intended to maintain sustained exposure within the lung, potentially supporting therapeutic activity while reducing systemic drug exposure. In preclinical studies, inhaled RZ-520 demonstrated robust therapeutic efficacy across multiple disease models, while also showing a favorable safety profile and negligible systemic exposure. Rezubio believes these characteristics could provide the foundation for a potentially differentiated treatment option for patients with chronic respiratory diseases, although the ongoing Phase 1 study will be important for establishing whether the candidate’s preclinical characteristics translate into humans.
First Phase 1 Study to Evaluate Safety and Pharmacology
The newly initiated Phase 1 clinical trial will focus on the fundamental clinical characteristics of RZ-520, including safety, tolerability, PK, and PD in healthy volunteers. First cohort dosing represents the initial clinical assessment of how the inhaled candidate behaves in humans and will provide data needed to guide subsequent development. The company’s strategy centers on delivering RZ-520 directly to the respiratory tract, with the objective of achieving sustained local drug exposure in the lung while limiting distribution into the wider systemic circulation. Such an approach could potentially improve the balance between efficacy and safety and may also offer dosing advantages for long-term management of chronic respiratory conditions. Rezubio said the dual FDA and NMPA IND clearances provide a regulatory foundation for advancing the program and support the company’s broader objective of developing tissue-targeted medicines using its MADD technology.
Advertisement
Rezubio Expands MADD Platform into Respiratory Diseases
Rezubio said the advancement of RZ-520 provides additional validation for its MADD platform, which is being used to develop tissue-targeted therapies against challenging diseases. The technology is designed to target cell-surface proteins and optimize the distribution and residence of therapeutic molecules in specific tissues. Beyond the respiratory tract, Rezubio is also applying the platform to potential therapies targeting the gastrointestinal (GI) tract, highlighting the company’s broader strategy to create medicines with differentiated tissue exposure and pharmacokinetic profiles. “The dual IND clearances from the FDA and NMPA and first cohort dosing of RZ-520 mark a pivotal milestone for both this program and our MADD platform,” said Yusheng Xiong, CEO of Rezubio. As the Phase 1 study progresses, clinical safety and pharmacology findings will determine the next development steps for RZ-520 and provide an early assessment of its potential as a novel inhaled therapy for chronic respiratory diseases. The program also represents an important test of whether Rezubio can translate the tissue-targeted design principles of its MADD platform into clinically meaningful therapeutic candidates.
Source: Rezubio press relese
